SXTP 0.98 60 Degrees Pharmaceuticals, Inc.
| Range: | 0.916-18.36 | Vol Avg: | 733678 | Last Div: | 0 | Changes: | 0.05 |
| Beta: | 5.27 | Cap: | 0.00B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Wed Jul 12 2023 | Empoloyees: | 3 | ||
| CUSIP: | 83006G104 | CIK: | 0001946563 | ISIN: | US83006G1040 | Country: | US |
| CEO: | Dr. Geoffrey Stuart Dow | Website: | https://60degreespharma.com | ||||
60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow